Schedule 13D ownership disclosure
Gemphire Therapeutics Inc.
Security class unavailable · CUSIP: 36870A108
Event date: 2019-07-24
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 1,586,987
- Percent of class
- 10.6000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-19-043766
- Form type
- SC 13D
- Filer
- Bisgaier Charles PhD
- CIK
- CIK 1381030
- Filed
- Aug 02, 2019
- Reporting period
- Jul 24, 2019
- Description
- Schedule 13D beneficial ownership